Inhibitors targeting FAM170A function through a variety of biochemical mechanisms, each distinctly influencing the protein's activity within the cell. Certain compounds effectively inhibit kinase activity, which is paramount in regulating phosphorylation processes critical for FAM170A function. By attenuating the activity of these kinases, the phosphorylation status of FAM170A can be altered, potentially leading to a decrease in its activity. Furthermore, the inhibition of mTOR pathway by specific inhibitors results in a reduction of protein synthesis, which may lead to decreased levels of FAM170A in the cell, hence impairing its functional activity. Additionally, compounds that hinder PI3K and MEK can disrupt the AKT and ERK signaling pathways respectively, which are known to be involved in the modulation of protein activities, including that of FAM170A. This disruption can result in a diminished functional state of FAM170A due to altered phosphorylation signaling.
Another set of inhibitors influence FAM170A activity by modulating various cellular pathways that indirectly impact the protein's function. For instance, the inhibition of JNK and p38 MAPK pathways can lead to a cascade of signaling events that ultimately reduce the activity of FAM170A. Proteasome inhibitors contribute to this regulatory landscape by affecting the degradation of regulatory proteins, which could in turn influence the functional activity of FAM170A. Additionally, compounds that interfere with the Hedgehog signaling pathway or EGFR signaling can create changes in the cellular environment that indirectly affect the activity of FAM170A. Furthermore, inhibitors that target Aurora kinases may disrupt cell cycle progression, which could have implications for FAM170A function. Lastly, the inhibition of glycolysis through compounds like 2-Deoxy-D-glucose may reduce cellular ATP levels, thereby potentially affecting the energy-dependent functions of FAM170A, highlighting the intricate web of cellular processes that can modulate its activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
A potent kinase inhibitor that targets multiple kinases which could affect FAM170A activity by altering phosphorylation processes. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
An mTOR inhibitor that can downregulate protein synthesis pathways, possibly reducing FAM170A levels and activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
A PI3K inhibitor that may decrease AKT signaling, consequently reducing the phosphorylation of proteins including FAM170A. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
An MEK inhibitor that could reduce ERK pathway signaling, potentially diminishing FAM170A's functional activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
A p38 MAPK inhibitor that might suppress downstream signaling affecting the function of FAM170A. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
A JNK inhibitor which may indirectly decrease the activity of FAM170A by modulating JNK pathway activity. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
A proteasome inhibitor that could lead to reduced degradation of proteins that regulate FAM170A activity. | ||||||
Cyclopamine | 4449-51-8 | sc-200929 sc-200929A | 1 mg 5 mg | $92.00 $204.00 | 19 | |
A Hedgehog pathway inhibitor that may alter the cellular context, indirectly affecting FAM170A activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
An ERK inhibitor that could suppress signaling pathways involving FAM170A. | ||||||
WZ 4002 | 1213269-23-8 | sc-364655 sc-364655A | 10 mg 50 mg | $180.00 $744.00 | 1 | |
An EGFR inhibitor that could decrease signaling pathways that modulate the activity of FAM170A. | ||||||